SCTT 11
Alternative Names: SCT-T11Latest Information Update: 17 Jan 2025
Price :
$50 *
At a glance
- Originator Sinocelltech
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Graves ophthalmopathy
Most Recent Events
- 10 Jan 2025 Preclinical trials in Graves ophthalmopathy in China (unspecified route) (NCT06769984)
- 10 Jan 2025 Sinocelltech plans a phase I/II trial for Graves ophthalmology, in February 2025 (NCT06769984)